Dasatinib
Signet Ring Adenocarcinoma of the Rectum
National Cancer Institute (NCI)Small moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Signet Ring Adenocarcinoma of the Rectum cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM University of Southern California | Phase 3 | BBB |
Eloxatin Virginia Commonwealth University | Phase 3 | BBB |
Irinotecan Fox Chase Cancer Center | Phase 3 | BBB |
Irinotecan National Cancer Institute (NCI) | Phase 3 | BB |
Aflibercept John Hays | Phase 2 | B |
View all 17 →
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →